These patients were participants in the double-blind , placebo-controlled randomized OmegAD study in which @ patients with mild Alzheimer 's disease ( AD ) received @ g n-@ FA -LSB- high in docosahexaenoic acid ( DHA ) -RSB- or placebo daily for @ months .